rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
11
|
pubmed:dateCreated |
2002-11-8
|
pubmed:abstractText |
Allogeneic blood stem cell transplantation (BSCT) can cure patients with hematologic malignancies by high-dose chemotherapy and allogeneic graft-vs-tumor (GvT) reactions. To avoid high-dose conditioning and evaluate engraftment, toxicity, and GvT reactions, we treated a group of high-risk patients with a minimal intensive conditioning regimen followed by allogeneic BSCT.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:status |
MEDLINE
|
pubmed:month |
Nov
|
pubmed:issn |
0301-472X
|
pubmed:author |
pubmed-author:AivadoManuelM,
pubmed-author:FenkRolandR,
pubmed-author:GattermannNorbertN,
pubmed-author:GermingUlrichU,
pubmed-author:HaasRainerR,
pubmed-author:HeyllAxelA,
pubmed-author:HildebrandtBarbaraB,
pubmed-author:KobbeGuidoG,
pubmed-author:KronenwettRalfR,
pubmed-author:NeumannFrankF,
pubmed-author:PapeHildegardH,
pubmed-author:RongAstridA,
pubmed-author:Royer-PokoraBrigitteB,
pubmed-author:SchneiderPeterP,
pubmed-author:SchubertDominiqueD,
pubmed-author:ZohrenFabianF
|
pubmed:issnType |
Print
|
pubmed:volume |
30
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1346-53
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:12423689-Adult,
pubmed-meshheading:12423689-Aged,
pubmed-meshheading:12423689-Aged, 80 and over,
pubmed-meshheading:12423689-Disease Progression,
pubmed-meshheading:12423689-Feasibility Studies,
pubmed-meshheading:12423689-Female,
pubmed-meshheading:12423689-Graft Survival,
pubmed-meshheading:12423689-Graft vs Host Disease,
pubmed-meshheading:12423689-Graft vs Leukemia Effect,
pubmed-meshheading:12423689-Graft vs Tumor Effect,
pubmed-meshheading:12423689-Hematologic Neoplasms,
pubmed-meshheading:12423689-Humans,
pubmed-meshheading:12423689-Leukemia, Myeloid,
pubmed-meshheading:12423689-Lymphoma,
pubmed-meshheading:12423689-Male,
pubmed-meshheading:12423689-Middle Aged,
pubmed-meshheading:12423689-Multiple Myeloma,
pubmed-meshheading:12423689-Myelodysplastic Syndromes,
pubmed-meshheading:12423689-Peripheral Blood Stem Cell Transplantation,
pubmed-meshheading:12423689-Remission Induction,
pubmed-meshheading:12423689-Risk,
pubmed-meshheading:12423689-Salvage Therapy,
pubmed-meshheading:12423689-Transplantation, Homologous,
pubmed-meshheading:12423689-Transplantation Chimera,
pubmed-meshheading:12423689-Transplantation Conditioning,
pubmed-meshheading:12423689-Treatment Outcome,
pubmed-meshheading:12423689-Whole-Body Irradiation
|
pubmed:year |
2002
|
pubmed:articleTitle |
Reliable engraftment, low toxicity, and durable remissions following allogeneic blood stem cell transplantation with minimal conditioning.
|
pubmed:affiliation |
Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University Düsseldorf, Düsseldorf, Germany. kobbe@med.uni-duesseldorf.de
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|